首页> 美国卫生研究院文献>other >Toward development of a surface enhanced Raman scattering (SERS) based cancer diagnostic immunoassay panel
【2h】

Toward development of a surface enhanced Raman scattering (SERS) based cancer diagnostic immunoassay panel

机译:朝向表面的发展增强拉曼散射(sERs)基础的癌症诊断用免疫面板

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Proteomic analyses of readily obtained human fluids (e.g., serum, urine, and saliva) indicate that the diagnosis of complex diseases will be enhanced by the simultaneous measurement of multiple biomarkers from such samples. This paper describes the development of a nanoparticle-based multiplexed platform that has the potential for simultaneous readout of large numbers of biomolecules. For this purpose, we have chosen pancreatic adenocarcinoma (PA) as a test bed for diagnosis and prognosis. PA is a devastating form of cancer in which an estimated 86% of diagnoses resulted in death in the United States in 2010. The high mortality rate is due, in part, to the asymptomatic development of the disease and the dearth of sensitive diagnostics available for early detection. One promising route lies in the development of a serum biomarker panel that can generate a signature unique to early stage PA. We describe the design and development of a proof-of-concept PA biomarker immunoassay array coupled with surface enhanced Raman scattering (SERS) as a sensitive readout method.
机译:容易获得的人体液体(例如血清,尿液和唾液)的蛋白质组学分析表明,通过同时测量此类样品中的多种生物标志物,可以增强对复杂疾病的诊断。本文介绍了一种基于纳米粒子的多路复用平台的开发,该平台具有同时读取大量生物分子的潜力。为此,我们选择了胰腺腺癌(PA)作为诊断和预后的试验床。 PA是一种毁灭性的癌症,据估计,2010年美国有86%的诊断导致死亡。高死亡率是部分原因在于该疾病无症状发展和缺乏可用的敏感诊断方法早期发现。一种有前途的途径在于开发可以产生早期PA特有的特征的血清生物标志物组。我们描述了概念验证的PA生物标志物免疫测定阵列与表面增强拉曼散射(SERS)结合作为敏感读出方法的设计和开发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号